Efficacy and Toxicity of Whole Brain Radiotherapy Plus Simultaneous Image Guided Intensity Modulation Radiotherapy Boost for Brain Metastases of NSCLC
L. Zhou,J. Liu,Y. Gong,R. Liu,B. Zou,S. Bai,J. Xiao,T. Li,M. Huang,Y. Lu
DOI: https://doi.org/10.1016/j.ijrobp.2010.07.1176
2010-01-01
Abstract:Purpose/Objective(s)To evaluate efficacy and toxicity of whole brain radiotherapy (WBRT) plus simultaneous image guided intensity modulation radiotherapy (IG-IMRT) boost for brain metastases of NSCLC not amenable to surgery.Materials/MethodsDuring June 2006 and April 2009, 29 non-small cell lung cancer (NSCLC) patients with 87 brain metastases were included in this prospective Phase II trial. All patients received WBRT at a dose of 40Gy/20f/4 weeks. 27 patients with metastases ≤6 received IG-IMRT boost at a dose of 20Gy/5f concurrent with WBRT in the fourth week; 2 patients with metastases >10 received IG-IMRT boost at a dose of 24Gy/8f, and whole metastases were separated into two parts according to their location in right or left half of brain, each part of metastases received IG-IMRT boost each other day from the beginning of WBRT. All patients were immobilized in non-invasive thermoplastic head masks (Med-Tec, U.S.A) and treated by Synergy linear accelerator (Elekta, Sweden) with 6MV X-ray.ResultsAfter a median follow-up of 9 months, the objective response rate (CR plus PR rate) was 69% (20/29), median progression-free survival was 10 months (95% CI: 5-14), median survival was 10 months (95% CI: 6-14), six-month and one-year survival rates were 65.5% and 38.8%. Univariate analysis revealed that adverse prognostic factors were male, uncontrolled primary tumor, non-adenocarcinoma, intracranial lesions ≥3, maximum lesion volume ≥3cc, and total volume of lesions ≥10cc. 13 patients died due to extracranial failure and 7 patients died due to intracranial failure. Patients with intracranial lesions ≥3 (54.5% vs. 11.1%, p = 0.043), maximum lesion volume ≥3cc (50% vs. 0%, p = 0.032) and total volume of lesions ≥10cc (66.7% vs. 9.1%, p = 0.007) had higher rates of death due to intracranial failure. CTC grade 1 and 2 radiation leukoencephalopathy were observed in 19 (65.5%) and 6 (20.7%) patients, grade 1 to 3 cognitive impairment were observed in 6 (20.7%), 3 (10.3%) and 3 (10.3%) patients. Rates of grade 2-3 cognitive impairment were higher in female (44.4% vs. 10%, p = 0.034), age ≥60 (38.5% vs. 6.3%, p = 0.033) patients and patients received EGFR-TKI therapy (45.5% vs. 5.6%, p = 0.01). In combination with survival analysis stated above, the higher rates of late toxicity in female patients and patients received EGFR-TKI therapy (almost was adenocarcinoma) might be on account of the longer survival of these patients.ConclusionsWBRT plus simultaneous IG-IMRT boost is an effective and safe treatment for brain metastases of NSCLC, especially for patients with number of lesions <3, maximum lesion volume <3cc and total volume of lesions <10cc. However, this treatment should be cautiously used to elderly patients because of the higher rate of late toxicity. Purpose/Objective(s)To evaluate efficacy and toxicity of whole brain radiotherapy (WBRT) plus simultaneous image guided intensity modulation radiotherapy (IG-IMRT) boost for brain metastases of NSCLC not amenable to surgery. To evaluate efficacy and toxicity of whole brain radiotherapy (WBRT) plus simultaneous image guided intensity modulation radiotherapy (IG-IMRT) boost for brain metastases of NSCLC not amenable to surgery. Materials/MethodsDuring June 2006 and April 2009, 29 non-small cell lung cancer (NSCLC) patients with 87 brain metastases were included in this prospective Phase II trial. All patients received WBRT at a dose of 40Gy/20f/4 weeks. 27 patients with metastases ≤6 received IG-IMRT boost at a dose of 20Gy/5f concurrent with WBRT in the fourth week; 2 patients with metastases >10 received IG-IMRT boost at a dose of 24Gy/8f, and whole metastases were separated into two parts according to their location in right or left half of brain, each part of metastases received IG-IMRT boost each other day from the beginning of WBRT. All patients were immobilized in non-invasive thermoplastic head masks (Med-Tec, U.S.A) and treated by Synergy linear accelerator (Elekta, Sweden) with 6MV X-ray. During June 2006 and April 2009, 29 non-small cell lung cancer (NSCLC) patients with 87 brain metastases were included in this prospective Phase II trial. All patients received WBRT at a dose of 40Gy/20f/4 weeks. 27 patients with metastases ≤6 received IG-IMRT boost at a dose of 20Gy/5f concurrent with WBRT in the fourth week; 2 patients with metastases >10 received IG-IMRT boost at a dose of 24Gy/8f, and whole metastases were separated into two parts according to their location in right or left half of brain, each part of metastases received IG-IMRT boost each other day from the beginning of WBRT. All patients were immobilized in non-invasive thermoplastic head masks (Med-Tec, U.S.A) and treated by Synergy linear accelerator (Elekta, Sweden) with 6MV X-ray. ResultsAfter a median follow-up of 9 months, the objective response rate (CR plus PR rate) was 69% (20/29), median progression-free survival was 10 months (95% CI: 5-14), median survival was 10 months (95% CI: 6-14), six-month and one-year survival rates were 65.5% and 38.8%. Univariate analysis revealed that adverse prognostic factors were male, uncontrolled primary tumor, non-adenocarcinoma, intracranial lesions ≥3, maximum lesion volume ≥3cc, and total volume of lesions ≥10cc. 13 patients died due to extracranial failure and 7 patients died due to intracranial failure. Patients with intracranial lesions ≥3 (54.5% vs. 11.1%, p = 0.043), maximum lesion volume ≥3cc (50% vs. 0%, p = 0.032) and total volume of lesions ≥10cc (66.7% vs. 9.1%, p = 0.007) had higher rates of death due to intracranial failure. CTC grade 1 and 2 radiation leukoencephalopathy were observed in 19 (65.5%) and 6 (20.7%) patients, grade 1 to 3 cognitive impairment were observed in 6 (20.7%), 3 (10.3%) and 3 (10.3%) patients. Rates of grade 2-3 cognitive impairment were higher in female (44.4% vs. 10%, p = 0.034), age ≥60 (38.5% vs. 6.3%, p = 0.033) patients and patients received EGFR-TKI therapy (45.5% vs. 5.6%, p = 0.01). In combination with survival analysis stated above, the higher rates of late toxicity in female patients and patients received EGFR-TKI therapy (almost was adenocarcinoma) might be on account of the longer survival of these patients. After a median follow-up of 9 months, the objective response rate (CR plus PR rate) was 69% (20/29), median progression-free survival was 10 months (95% CI: 5-14), median survival was 10 months (95% CI: 6-14), six-month and one-year survival rates were 65.5% and 38.8%. Univariate analysis revealed that adverse prognostic factors were male, uncontrolled primary tumor, non-adenocarcinoma, intracranial lesions ≥3, maximum lesion volume ≥3cc, and total volume of lesions ≥10cc. 13 patients died due to extracranial failure and 7 patients died due to intracranial failure. Patients with intracranial lesions ≥3 (54.5% vs. 11.1%, p = 0.043), maximum lesion volume ≥3cc (50% vs. 0%, p = 0.032) and total volume of lesions ≥10cc (66.7% vs. 9.1%, p = 0.007) had higher rates of death due to intracranial failure. CTC grade 1 and 2 radiation leukoencephalopathy were observed in 19 (65.5%) and 6 (20.7%) patients, grade 1 to 3 cognitive impairment were observed in 6 (20.7%), 3 (10.3%) and 3 (10.3%) patients. Rates of grade 2-3 cognitive impairment were higher in female (44.4% vs. 10%, p = 0.034), age ≥60 (38.5% vs. 6.3%, p = 0.033) patients and patients received EGFR-TKI therapy (45.5% vs. 5.6%, p = 0.01). In combination with survival analysis stated above, the higher rates of late toxicity in female patients and patients received EGFR-TKI therapy (almost was adenocarcinoma) might be on account of the longer survival of these patients. ConclusionsWBRT plus simultaneous IG-IMRT boost is an effective and safe treatment for brain metastases of NSCLC, especially for patients with number of lesions <3, maximum lesion volume <3cc and total volume of lesions <10cc. However, this treatment should be cautiously used to elderly patients because of the higher rate of late toxicity. WBRT plus simultaneous IG-IMRT boost is an effective and safe treatment for brain metastases of NSCLC, especially for patients with number of lesions <3, maximum lesion volume <3cc and total volume of lesions <10cc. However, this treatment should be cautiously used to elderly patients because of the higher rate of late toxicity.